Max Nisen
Health care columnist for Bloomberg Opinion @bopinion. TTP/Go Birds. I write a newsletter on cooking and eating called Fresser: tinyletter.com/Fresser
Last synced from Twitter 82d ago
Why You Shouldn’t Worry About Studies Showing Waning Coronavirus Antibodies
Experts say it’s normal for levels of antibodies to drop after clearing an infection, and that they represent just one arm of the immune response against a virus.
Bloomberg - Are you a robot?
Max Nisen
It's tempting to count on vaccines and treatments to solve Covid for us soon, indeed that seems to be WH policy at the moment. That strategy is sure to disappoint.
83d
Bloomberg - Are you a robot?
1
Max Nisen
NIH/Lilly halting trial of its antibody therapy in hospitalized patients. Not related to safety pause -- lack of efficacy. Reason to expect it'd work better earlier (confirmatory trial ongoing) but not a positive for its commercial prospects/impact.
84d
Bloomberg - Are you a robot?
Max Nisen
Our recent editorial on how Trump can't be trusted on the issue bloomberg.com/opinion/articl…
From me earlier on how the pandemic makes his vacuity on the issue even more ridiculous, esp. in comparison to Dem proposals to expand coverage bloomberg.com/opinion/articl…
88d
VRBPAC October 22, 2020 Meeting Announcement
This is the CBER Vaccines and Related Biological Products Advisory Committee October 22, 2020 Meeting Announcement.
Racial Data Dashboard
The COVID-19 pandemic isn’t affecting all communities the same way. The COVID Racial Data Dashboard helps us track this inequity by publishing topline racial data compared with state demographic data.
Max Nisen
Didn't get a screenshot, but excellent @COVID19Tracking data on the disproportionate impact of the pandemic on minority populations cited in the NIH presentation at the FDA vaccine adcom
88d
SABEW20 Xana Fellowship
Are you a motivated female news mid-level news manager in search of advancement? SABEW wants to help you meet your professional goals and become your best self! We’re offering 10…
An angry Azar floats plans to oust FDA’s Hahn
Fights over vaccine standards have created an unbridgeable divide within HHS, officials said, but White House is unlikely to approve any changes until after the election.
Bloomberg - Are you a robot?
Max Nisen
Big pharma will start making money on Covid drugs at some point, but for now testing is the moneymaker
89d
Coronavirus Disease 2019 (COVID-19)
CDC is responding to the novel (new) coronavirus (COVID-19) outbreak.
The Tricky Business Of Coronavirus Testing On College Campuses : Short Wave
We hit the road with NPR Education Reporter Elissa Nadworny. She's been on a weekslong road trip to get an up-close view of how colleges across the U.S. are handling the pandemic. On today's show, she tells us how one university has been using mass...
Bloomberg - Are you a robot?
Max Nisen
The U.S. is testing a lot more than it did in the spring/summer. But the boost is very much not equally distributed, with red states tending to test less. That's a concerning trend as cases rise and winter approaches. bloomberg.com/opinion/articl… pic.twitter.com/AuEBPBI95H
94d
An Open Letter from Pfizer Chairman and CEO Albert Bourla | Pfizer
As we get closer to an important data readout from our COVID-19 vaccine program, I wanted to speak directly to the billions of people, millions of businesses and hundreds of governments around the world that are investing their hopes in a safe and...
1
Max Nisen
Pfizer out with a very clear statement on vaccine timing. If it gets positive data (regardless of when it comes) it will apply for an EUA only when it has enough safety data to meet FDA standard -- which it expects would be the third week of November.
94d